GlassScriptPhysician profile
Danay Marante
NPI 1811418205
$2,703.57
in general payments reported to CMS, 2019-2025
17 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $356 · 2023: $1,031 · 2024: $774 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $521.90 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $445.30 | 2021-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $389.58 | 2022-2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $329.99 | 2023-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $312.45 | 2022-2025 | Ingrezza |
| Abbvie INC. | $256.10 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $120.74 | 2021 | |
| Alkermes, INC. | $112.17 | 2023 | Lybalvi |
| Lundbeck LLC | $45.92 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $35.98 | 2023-2024 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2024-2025 | Trintellix |
| Corium, LLC | $23.81 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $18.36 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.96 | 2025 | Cobenfy |
| Tris Pharma INC | $13.46 | 2024 | Dyanavel Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $13.36 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $13.07 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danay Marante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.